Galapagos Puts Faith In Refocused Pipeline To Regain Investor Confidence
After High-Profile Setbacks In The Clinic
The Belgian biotech's president, Bart Filius, tells Scrip that exiting the metabolic disease and osteoarthritis space and focusing on inflammation makes sense to "bring a bit more balance in terms of risk into our portfolio."
You may also be interested in...
Some 22 years after founding what was one of the biggest success stories in Europe's biotech sector before a recent series of setbacks in the clinic struck, Onno van de Stolpe has decided to retire as Galapagos CEO and the search has already started for his successor.
In this week's podcast episode of Five Must-Know Things, hear about issues surrounding the proposed IP waiver for coronavirus vaccines, a trial delay for Novavax’s COVID-19 vaccine, an ICER review of multiple myeloma drugs and Galapagos’ efforts to refocus its R&D pipeline.
Together with a similar delay for AbbVie’s Rinvoq, the delays appear to stem from a study that raised concerns about the class. But the potential sales impact is less clear.